biostudies-literatureUnknown27(8)Kawamoto YEli Lilly Japan K.K.<h4>Background</h4>Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.<h4>Materials and methods</h4>Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug.<h4>ResultThe oncologiste642-e649https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355819biostudies-literaturePhase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.PMC9355819Dazai MNakamura MKomatsu YSato ATsuji YOkada KSakamoto NSakata YShindo YMeguro TYuki SHarada KSogabe SSekiguchi MSawada KIshiguro AIto YMKawamoto YOkuda HMuto OfalsePhase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.<h4>Background</h4>Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.<h4>Materials and methods</h4>Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug.<h4>Result2022-01-01T00:00:00Z2022 Aug2025-04-22T11:30:28.761Z2025-04-05T23:57:28.872ZS-EPMC93558193557951110.1093/oncolo/oyac086